Matches in SemOpenAlex for { <https://semopenalex.org/work/W1867445539> ?p ?o ?g. }
- W1867445539 endingPage "1771" @default.
- W1867445539 startingPage "1757" @default.
- W1867445539 abstract "Oncolytic viruses (OVs) selectively replicate in tumor cells and cause cancer cell death. Most OVs in clinical studies are genetically engineered. In contrast, the avian Newcastle disease virus (NDV) is a naturally oncolytic RNA virus. While anti-viral immunity is considered a major problem in achieving maximal tumor cell killing by OVs, this review discusses the importance of NDV immunogenic cell death (ICD) and how anti-viral immune responses can be integrated to induce maximal post-oncolytic T-cell-mediated anti-tumor immunity. Since replication of NDV is independent of host cell DNA replication (which is the target of many cytostatic drugs and radiotherapy) and because of other findings, oncolytic NDV is a candidate agent to break therapy resistance of tumor cells.Properties of this avian paramyxovirus are summarized with special emphasis to its anti-neoplastic and immune-stimulatory properties. The review then discusses prospective anti-cancer therapies, including treatments with NDV alone, and combinations with an autologous NDV-modified tumor cell vaccine or with a viral oncolysate pulsed dendritic cell vaccine. Various combinatorial approaches between these and with other modalities are also reviewed.Post-oncolytic anti-tumor immunity based on ICD is in the expert's opinion of greater importance for long-term therapeutic effects than maximal tumor cell killing. Of the various combinatorial approaches discussed, the most promising and feasible for clinical practice appears to be the combination of systemic NDV pre-treatment with anti-tumor vaccination." @default.
- W1867445539 created "2016-06-24" @default.
- W1867445539 creator A5022678830 @default.
- W1867445539 date "2015-10-05" @default.
- W1867445539 modified "2023-10-13" @default.
- W1867445539 title "Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance" @default.
- W1867445539 cites W1581947446 @default.
- W1867445539 cites W1604374121 @default.
- W1867445539 cites W1720669243 @default.
- W1867445539 cites W1767250819 @default.
- W1867445539 cites W1827205385 @default.
- W1867445539 cites W1894525365 @default.
- W1867445539 cites W1910257954 @default.
- W1867445539 cites W1917241653 @default.
- W1867445539 cites W1931089671 @default.
- W1867445539 cites W1966174118 @default.
- W1867445539 cites W1968954675 @default.
- W1867445539 cites W1970718186 @default.
- W1867445539 cites W1972455109 @default.
- W1867445539 cites W1974026073 @default.
- W1867445539 cites W1980077869 @default.
- W1867445539 cites W1985590638 @default.
- W1867445539 cites W1986345863 @default.
- W1867445539 cites W1986830366 @default.
- W1867445539 cites W1996912191 @default.
- W1867445539 cites W2006182783 @default.
- W1867445539 cites W2008757142 @default.
- W1867445539 cites W2013637325 @default.
- W1867445539 cites W2014687480 @default.
- W1867445539 cites W2015445708 @default.
- W1867445539 cites W2017515700 @default.
- W1867445539 cites W2017962679 @default.
- W1867445539 cites W2020912978 @default.
- W1867445539 cites W2024794613 @default.
- W1867445539 cites W2025822934 @default.
- W1867445539 cites W2027585770 @default.
- W1867445539 cites W2029765161 @default.
- W1867445539 cites W2032024736 @default.
- W1867445539 cites W2036044673 @default.
- W1867445539 cites W2040797778 @default.
- W1867445539 cites W2044504047 @default.
- W1867445539 cites W2049092411 @default.
- W1867445539 cites W2050129581 @default.
- W1867445539 cites W2050623855 @default.
- W1867445539 cites W2058676815 @default.
- W1867445539 cites W2060816835 @default.
- W1867445539 cites W2065228810 @default.
- W1867445539 cites W2066671159 @default.
- W1867445539 cites W2070694328 @default.
- W1867445539 cites W2070805755 @default.
- W1867445539 cites W2072930839 @default.
- W1867445539 cites W2074642660 @default.
- W1867445539 cites W2081534970 @default.
- W1867445539 cites W2082041718 @default.
- W1867445539 cites W2085382152 @default.
- W1867445539 cites W2086544069 @default.
- W1867445539 cites W2093593198 @default.
- W1867445539 cites W2094130407 @default.
- W1867445539 cites W2094207047 @default.
- W1867445539 cites W2095747507 @default.
- W1867445539 cites W2097995306 @default.
- W1867445539 cites W2099295163 @default.
- W1867445539 cites W2100025280 @default.
- W1867445539 cites W2108114224 @default.
- W1867445539 cites W2110490823 @default.
- W1867445539 cites W2112979138 @default.
- W1867445539 cites W2113309441 @default.
- W1867445539 cites W2113847305 @default.
- W1867445539 cites W2114972374 @default.
- W1867445539 cites W2116672872 @default.
- W1867445539 cites W2118546263 @default.
- W1867445539 cites W2118982164 @default.
- W1867445539 cites W2120426523 @default.
- W1867445539 cites W2121436255 @default.
- W1867445539 cites W2123291849 @default.
- W1867445539 cites W2125495568 @default.
- W1867445539 cites W2126427198 @default.
- W1867445539 cites W2129551759 @default.
- W1867445539 cites W2137045685 @default.
- W1867445539 cites W2137322846 @default.
- W1867445539 cites W2141674300 @default.
- W1867445539 cites W2143099538 @default.
- W1867445539 cites W2145228084 @default.
- W1867445539 cites W2145255008 @default.
- W1867445539 cites W2157408208 @default.
- W1867445539 cites W2159489772 @default.
- W1867445539 cites W2161955289 @default.
- W1867445539 cites W2165790025 @default.
- W1867445539 cites W2170739773 @default.
- W1867445539 cites W2221279807 @default.
- W1867445539 cites W2319008999 @default.
- W1867445539 cites W2321874491 @default.
- W1867445539 cites W2323343322 @default.
- W1867445539 cites W358922134 @default.
- W1867445539 cites W4211238487 @default.
- W1867445539 cites W4236037905 @default.
- W1867445539 doi "https://doi.org/10.1517/14712598.2015.1088000" @default.
- W1867445539 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26436571" @default.